サマリー

The global antibiotics market exhibited moderate growth during 2015-2020. Antibiotics are a group of medicines, such as penicillin, cephalosporin, fluoroquinolone, etc., that inhibit the growth of microorganisms, prevent the replication of parasites, and reduce serious complications of bacterial infections. They are generally administered orally in the form of pills, liquids, tablets, and capsules. They are also available as sprays, creams, ointments, and lotions, which are applied topically on the skin to treat certain acne and other skin diseases. Moreover, antibiotics can be administered through an injection or intravenously (IV) for severe infections according to the signs and symptoms of the patients.

The growing prevalence of infectious diseases, such as malaria, tuberculosis, pneumonia, and acquired immunodeficiency syndrome (AIDS), along with the easy availability of generic medicines, represents one of the major factors positively influencing the demand for antibiotics. Moreover, the topical application of antibiotics offers reduced potential for systemic absorption and toxicity and minimizes the risk of surgical site infections. Consequently, the rising number of surgical procedures is increasing the sales of antibiotics to prevent incision infection. They can also be utilized in the form of drops for conjunctivitis and acute ear infections. Furthermore, antibiotics are finding extensive application in livestock farming to safeguard animal health and welfare and support food safety. Apart from this, scientists are developing less reactogenic, cell-free vaccines consisting of purified components, inactivated toxins, and proteins. Additionally, several health organizations are entering into strategic partnerships with private companies to deliver new treatments and improve existing drugs. Looking forward, IMARC Group expects the global antibiotics market to grow at a CAGR of 4.5% during the forecast period (2021-2026).

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antibiotics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, action mechanism, drug class, spectrum of activity, route of administration and end user.

Breakup by Action Mechanism:

Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others

Breakup by Drug Class:

Cephalosporin
Penicillin
Fluoroquinolone
Macrolide
Carbapenem
Aminoglycoside
Others

Breakup by Spectrum of Activity:

Broad-Spectrum Antibiotics
Narrow-Spectrum Antibiotics

Breakup by Route of Administration:

Oral
Parenteral
Topical
Others

Breakup by End User:

Hospitals
Specialty Clinics
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan Plc (AbbVie Inc.), Basilea Pharmaceutica AG, GlaxoSmithKline Plc, Johnson & Johnson, Melinta Therapeutics, Merck & Co. Inc., Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Spero Therapeutics and Tetraphase Pharmaceuticals.

Key Questions Answered in This Report:
How has the global antibiotics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global antibiotics market?
What are the key regional markets?
What is the breakup of the market based on the action mechanism?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the spectrum of activity?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global antibiotics market and who are the key players?
What is the degree of competition in the industry?

ページTOPに戻る

目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Antibiotics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Action Mechanism
6.1 Cell Wall Synthesis Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Protein Synthesis Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 DNA Synthesis Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 RNA Synthesis Inhibitors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Mycolic Acid Inhibitors
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Drug Class
7.1 Cephalosporin
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Penicillin
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Fluoroquinolone
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Macrolide
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Carbapenem
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Aminoglycoside
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Spectrum of Activity
8.1 Broad-Spectrum Antibiotics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Narrow-Spectrum Antibiotics
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Route of Administration
9.1 Oral
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Parenteral
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Topical
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by End User
10.1 Hospitals
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Specialty Clinics
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Others
10.3.1 Market Trends
10.3.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia-Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Allergan Plc (AbbVie Inc.)
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 SWOT Analysis
16.3.2 Basilea Pharmaceutica AG
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.3 GlaxoSmithKline Plc
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 Johnson & Johnson
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Melinta Therapeutics
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.6 Merck & Co. Inc.
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 Financials
16.3.6.4 SWOT Analysis
16.3.7 Nabriva Therapeutics Plc
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.8 Paratek Pharmaceuticals Inc.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.9 Pfizer Inc.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Sanofi SA
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.10.4 SWOT Analysis
16.3.11 Spero Therapeutics
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.12 Tetraphase Pharmaceuticals
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio